It is currently unknown whether intensive blood pressure (BP) lowering beyond that recommended would lead to more lowering of the risk of left ventricular hypertrophy (LVH) in patients with hypertension and whether reducing the risk of LVH explains the reported cardiovascular disease (CVD) benefits of intensive BP lowering in this population.
L
eft ventricular hypertrophy (LVH), a common finding in patients with hypertension, is a maladaptive response to chronic pressure overload. 1 Successful management of high blood pressure (BP) modifies this response and produces regression of LVH, and selection of individual antihypertensive drugs appears to be less important than the management of BP itself. 2 In patients with both hypertension and diabetes mellitus, we have recently shown that more intensive lowering of BP (target systolic BP [SBP] <120 mm Hg) leads to more reduction in the risk of LVH. 3 Similar results were reported from a small clinical trial in which SBP lowering to <130 mm Hg was compared with a goal of <140 mm Hg in adults ≥55 years of age without diabetes mellitus. 4 However, it is yet to be established whether a more intensive lowering (target SBP <120 mm Hg) in a diverse population with hypertension without diabetes mellitus will result in a lower risk of LVH compared with standard BP lowering (target SBP <140 mm Hg).
Development of LVH is known to be associated with a greater risk of cardiovascular disease (CVD) morbidity and mortality, and this risk could be reversed by regression of LVH. [5] [6] [7] [8] [9] [10] [11] In the Framingham Heart Study, regression in the electrocardiographic Cornell voltage LVH criteria was associated with a lower risk of clinical CVD, whereas progression in Cornell voltage identified individuals at increased risk of CVD. 5 Similar conclusions were reported from MRFIT (Multiple Risk-Factor Intervention Trial), 6 HOPE (Heart Outcomes Prevention Evaluation), 7 and LIFE (Losartan Intervention For End Point Reduction in Hypertension Study). [8] [9] [10] [11] In SPRINT (Systolic Blood Pressure Intervention Trial), which included patients with hypertension but no diabetes mellitus, intensive BP lowering targeting a SBP of <120 mm Hg, compared with standard SBP lowering targeting <140 mm Hg, resulted in lower rates of CVD events. 12 Whether this effect of intensive BP lowering on reducing CVD events could be explained by its effect on LVH is also currently unknown.
Therefore, we examined the differential impact of intensive BP lowering (target SBP <120 mm Hg) versus standard BP lowering (target SBP <140 mm Hg) on LVH in SPRINT, a randomized, multicenter trial involving middle-aged and older patients with hypertension but no diabetes mellitus. We also examined whether the positive effect of intensive BP lowering on the CVD outcomes in SPRINT is explained by its effect on LVH.
METHODS

Study Population and Design
SPRINT was a randomized, controlled, open-label trial that was conducted at 102 clinical sites organized into 5 clinical center networks in the United States. The rationale and design of the SPRINT trial have been published elsewhere. 12, 13 Briefly, SPRINT aimed to test whether reducing SBP to <120 mm Hg reduces CVD events, defined as a composite of nonfatal myocardial infarction, acute coronary syndrome not resulting in myocardial infarction, nonfatal stroke, nonfatal acute decompensated heart failure, and death resulting from CVD (SPRINT primary outcome). Participants were required to meet all the following criteria: age of at least 50 years, SBP of 130 to 180 mm Hg, and an increased risk of CVD defined as presence of 1 or more of the following: clinical or subclinical CVD, chronic kidney disease, a 10-year risk of CVD ≥15% estimated by the Framingham risk score, or age ≥75 years. Patients with type 2 diabetes mellitus or prior stroke were excluded.
A total of 9361 participants were enrolled between November 2010 and March 2013, of whom 4683 were randomized to a SBP target of <140 mm Hg (standard treatment arm) and 4678 participants were randomized to <120 mm Hg (intensive treatment arm). Randomization was stratified by clinical site. The SPRINT intervention was stopped early (median follow-up, 3.26 years) because of a 25% reduction in the primary composite CVD end point and a 27% reduction in all-cause mortality in the intensive treatment group. The study was approved by the institutional review board at each participating site, and written informed consent was obtained from all participants.
For the purpose of this analysis, we included SPRINT participants with baseline and at least 1 follow-up ECG. On the other hand, we excluded participants with missing or uninterpretable baseline ECG (n=138) and those without any followup ECG (n=1059).
Clinical Perspective
What Is New? What Are the Clinical Implications?
• These findings add further evidence of the benefits of intensive blood pressure lowering in patients with hypertension and suggest that these benefits go beyond reducing the hemodynamic stress on the cardiac structure.
• Further research is needed to understand the mediating factors and the mechanisms by which intensive blood pressure lowering affects the cardiovascular system. 3 amplitude) using the following sex-specific cutoff points: ≥2200 µV in women and ≥2800 µV in men.
Ascertainment of LVH
14 LVH was considered present or absent (or changed from one status to another) on the basis of crossing these cutoff points up or down. In addition to LVH as a categorical/binary variable, Cornell voltage was examined as a continuous variable (referred to here as Cornell index). Using Cornell voltage as a continuous variable has the advantage of being not dependent on the cutoff points selected to define LVH, and it is more sensitive to changes during follow-up than LVH as a categorical variable. 3 In sensitivity analysis, we also used Cornell voltage product ([RaVL amplitude+SV 3 amplitude]×QRS duration) 15 and Sokolow-Lyon (SV 1 amplitude+RV 5 /V 6 amplitude) 16 LVH criteria. In addition, we used LVH by Minnesota Code ECG classification, which represents LVH criteria with ST/T abnormalities (LVH with strain pattern) in selected analyses that do not requires the use of continuous measures (such Cornell index). Minnesota Code LVH is defined as high-amplitude R waves (Minnesota 
Events and Other Study Measurements
Demographic data were collected at baseline before randomization. Clinical and laboratory data were obtained at baseline and every 3 months thereafter. Details of the assessment of BP, adjustment of medication doses, and antihypertensive drug regimens during the trial are provided elsewhere. 13 At each visit, trained clinical staff measured BPs with an automated BP device (Omron-HEM-907 XL, Omron Healthcare, Inc, Bannockburn, IL) using standardized procedures. 13 BP measurement requirements included measuring BP early in the visit and not after stressful examination components such as blood draws, proper positioning of the participant in a chair with back support, and proper cuff size determination. The manual of procedures stated that participants should be resting, not completing questionnaires, and not speaking with study staff during the 5-minute rest period or while BP measurements were being taken. The manual of procedures also stated that staff should leave the room during the 5-minute rest period and provided a script that staff could use to explain that they would be absent during the 5-minute rest period and would then enter the room and obtain the measurements without speaking to the participant. At 1 year, the SBP fell in the intensive treatment group by ≈15 mm Hg more than in the standard treatment group (mean SBP, 121.4 versus 136.2 mm Hg) with administration of an average of 1 more antihypertensive medication.
A structured interview was used in both treatment arms every 3 months to obtain self-reported CVD outcomes. Medical records and ECG data were obtained for documentation of events. Whenever clinical site staff became aware of a death, a standard protocol was used to obtain information on the event. Members of a committee who were unaware of the study group assignments adjudicated the clinical outcomes specified in the protocol. Details on the adjudication of these outcomes, including the CVD events, have been published elsewhere. 12 The CVD outcomes in this analysis included events through August 20, 2015, similar to the main report from the SPRINT trial but limited to the sample with a good-quality baseline ECG and at least 1 follow-up ECG.
Statistical Analyses
We used Cox proportional hazards regression to compare the time to the first occurrence of LVH in those without baseline LVH and to the first occurrence of regression of LVH (ie, recovery from LVH) in those with baseline LVH, separately, between the treatment arms. Clinical site at randomization was used as a stratification factor. Follow-up time was censored on the date of last ECG. Interactions between treatment effect and SPRINT prespecified subgroups (age [<75 versus ≥75 years], sex, race [black versus nonblack], SBP tertiles [≤132, >132 to <145, ≥145 mm Hg], prior CVD, and prior chronic kidney disease) were assessed with a likelihood ratio test for the interaction with the use of Hommel-adjusted 18 P values. To examine whether the impact of intensive BP lowering on the primary outcome is explained by its impact on LVH, we examined the magnitude of attenuation of the association between intensive (versus standard) BP lowering and the SPRINT primary CVD outcome after adjusting for LVH as a time-varying covariate. Similar to the main SPRINT results publication, 12 Cox proportional hazards regression with stratification according to clinic was used for this purpose.
Several additional analyses were conducted as follows. First, we compared the rate of regression of the mean Cornell index during follow-up (as a continuous variable) between the intensive and standard arms. In this analysis, we used linear mixed-effects models adjusting for baseline value of the Cornel index. Specifically, we looked at random slope and intercept models for each individual to have a separate intercept and slope for the longitudinal change in Cornell index over time and for there to be population-averaged intercepts and slopes. Second, we conducted sensitivity analysis in which we excluded 718 participants with major intraventricular conduction delay. This was done because the ECG diagnosis of LVH in those individuals needs to be interpreted with caution according to the current guidelines for the use of ECG criteria for detection of cardiac chamber enlargement. 19 Major intraventricular conduction included all participants with complete left and right bundle-branch blocks, Wolf-Parkinson-White syndrome, ventricular pacemaker, and major nonspecific conduction delay (all with QRS duration ≥120 millisecond). Finally, we used Cornell voltage product and Sokolow-Lyon LVH criteria in analyses similar to those used for Cornell voltage to confirm the results, as well as Minnesota Code LVH in ORIGINAL RESEARCH ARTICLE selected analyses that involve LVH as a categorical variable only (ie, present versus absent analysis only).
Statistical analyses were performed with SAS version 9.4 (SAS Institute Inc, Cary, NC). For Cox regression models, the proportional hazards assumption was checked and was met.
All P values reported were 2 sided, and statistical significance threshold was chosen as 5%.
RESULTS
A total of 8164 participants (mean age, 67.9 years; 35.3% women; 31.2% blacks) were included in the analysis (4086 from the intensive BP lowering and 4078 from the standard BP lowering). About 7.4% (n=605) of the participants had LVH at baseline, with a similar prevalence in both arms (302 in the intensive BP-lowering arm and 303 in the standard BP arm). The baseline characteristics of the study participants did not differ by treatment arms in the study overall or in subgroups stratified by LVH status. Table 1 shows the baseline characteristics of the overall sample, and Tables I and II in the online-only Data Supplement show the baseline characteristics in those without and with baseline LVH, respectively.
Among SPRINT participants without LVH at baseline (n= 7559) and during a median follow-up of 3.81 years, 324 new cases of LVH occurred (118 in the intensive BP-lowering arm and 206 in the standard BP arm). Intensive (compared with standard) BP lowering was associated with a 46% (P<0.001) lower risk of developing LVH (Table 2) . These results were consistent across subgroups of age, sex, race, SBP levels, prior CVD, and prior chronic kidney disease (Figure 1) .
Similarly, regression (improvement) of LVH was more common in the intensive versus standard BP-lowering arm. Among SPRINT participants with baseline LVH (n=605), 62% (n=377) showed regression of (recovery from) their LVH (211 [70%] in the intensive BP-lowering arm versus 166 [55%] in the standard BP arm). Participants assigned to the intensive (compared with standard) BP lowering were 66% (P<0.001) more likely to regress their LVH ( Table 3 ). These results were consistent among subgroups of SPRINT participants stratified by age, sex, race, SBP levels, and prior chronic kidney disease, but the effect was stronger in those with prior CVD compared with those without prior CVD (interaction P=0.001; Figure 2 ). With the use of random-coefficient models in all participants with and without baseline LVH, the rate of regression of Cornell voltage index (the sum of the amplitude of RaVL+SV 3 ) was faster in the intensive BPlowering arm than that in the standard arm by −33.7 µV/y (95% confidence interval [CI], −39.6 to −27.8; P<0.001; Table 4 ).
Similar effects of intensive BP lowering on LVH were observed with LVH criteria other than the Cornell voltage criteria we used in the main analysis. As shown in Table III ORIGINAL RESEARCH ARTICLE (HR=1.57; 95% CI, 1.03, 2.42) in SPRINT participants with LVH when these criteria were used at baseline, as shown in Table IV in the online-only Data Supplement.
With the use of random-coefficient models in all participants with and without baseline LVH, the rates of regression of Cornell voltage product index and SokolowLyon index (ie, as continuous variables) were also faster in the intensive BP-lowering arm than in the standard arm, similar to what was observed in the main analysis with Cornell voltage index ( 
DISCUSSION Principal Findings
In this post hoc analysis from the SPRINT trial, we examined the effect of intensive BP lowering on the risk of LVH and whether this effect explains the reported cardiovascular benefits of intensive BP lowering in patients with hypertension at high risk for CVD but no diabetes mellitus. The key findings are the following: (1) Intensive BP lowering compared with standard BP lowering resulted in lower rates of developing new LVH in those without LVH, with these results consistent among several subgroups of SPRINT participants; (2) intensive BP lowering compared with standard BP lowering resulted in more regression of LVH in those with existing LVH, with the effect of intensive BP lowering on regression of LVH stronger in those with than in those without prior CVD but consistent across other subgroups; (3) the benefit of CVD risk reduction associated with intensive BP lowering was not substantially attenuated after adjustment for LVH as a time-varying covariate; and (4) there was no effect modification of the baseline LVH status on the relationship between intensive BP lowering and SPRINT primary CVD outcome.
These results taken together indicate that intensive BP lowering resulted in lower rates of LVH in the SPRINT trial by reducing the risk of developing new LVH and improving existing LVH. This favorable impact on LVH, however, appears to explain little of the reduction in CVD events associated with intensive BP lowering in SPRINT. Standard blood pressure lowering 4086 -5.6 (-9.8 to -1.4)
The Cornell index is defined as the sum of the R amplitude in aVL and S amplitude in V 3 in microvolts. The model was adjusted for baseline Cornell index value. CI indicates confidence interval; and SPRINT, Systolic Blood Pressure Intervention Trial. The Cornell index is the sum of the R amplitude in aVL and S amplitude in V 3 in microvolts. SPRINT primary cardiovascular disease outcome is the first occurrence of myocardial infarction, acute coronary syndrome, stroke, heart failure, or death resulting from cardiovascular causes. CI indicates confidence interval; LVH, left ventricular hypertrophy; and SPRINT, Systolic Blood Pressure Intervention Trial. *In the model, ECG LVH was associated with almost double the risk of cardiovascular disease events (hazard ratio=1.99; 95% CI, 1.53-2.57; P<0.001).
†In the same model, each 1-SD (669 µV) increase in mean Cornell voltage index was associated with a 23% increased risk of cardiovascular disease events (hazard ratio=1.23; 95% CI, 1.13-1.32; P<0.001).
ORIGINAL RESEARCH ARTICLE
Results in Context
LVH is an adaptive response to the wall stress associated with increased impedance to ventricular emptying caused by increased peripheral resistance occurring as a result of high BP. 20 This explains results from several prior reports showing that regression of LVH is possible by interventions aimed at lowering high BP. [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] However, these studies were not designed to examine whether lowering BP beyond a standard goal of <140 to 150/90 mm Hg is associated with greater reduction of the risk of LVH. Only 2 trials, however, have tried to answer this question. In the CardioSis trial (Controllo della Pressione Arteriosa Sistolica; 1111 participants without diabetes mellitus and with at least 1 CVD risk factor), lowering of SBP to <130 mm Hg decreased the likelihood of ECG LVH by 39% compared with usual lowering to SBP <140 mm Hg. 4 In the ACCORD BP trial (Action to Control Cardiovascular Risk in Diabetes-Blood Pressure; 4331 participants with hypertension with diabetes mellitus and at high risk of CVD), intensive BP lowering (target SBP to <120 mm Hg) resulted in a similar 39% reduction in LVH risk compared with standard BP lowering (target <140 mm Hg). 3 To the best of our knowledge, our results from the SPRINT trial are the first to provide evidence from a randomized clinical trial that includes a large diverse population of patients with hypertension without diabetes mellitus to suggest that intensive BP lowering (SBP <120 mm Hg) is associated with a lower risk of LVH compared with standard BP lowering (SBP <140 mm Hg).
Although mechanical stress resulting from pressure overload is the major driver for LVH in patients with hypertension, it is currently recognized that neurohormonal abnormalities also play an important role. Neurohormonal substances such as angiotensin II, aldosterone, norepinephrine, and insulin can directly promote myocyte hypertrophy and matrix deposition independently of their effects on systemic arterial pressure. 31 This could explain why, although successful lowering of SBP in our study caused regression of LVH in a large proportion of SPRINT participants with baseline LVH (62% total; 70% in intensive arm, and 55% in standard arm), some patients remained with LVH. It also has been reported that LVH can lead to irreversible fibrosis and scars in the myocardium that may not be responsive to antihypertensive treatment, 32 which also could explain why successful BP lowering did not improve all LVH and suggests that preventing the development of LVH rather than treating it may be a better strategy.
We also found that the benefit of intensive BP lowering on the risk of CVD events was not meaningfully influenced by its favorable effect on LVH. This suggests that the effect of intensive BP lowering on CVD may be through different mechanisms and LVH is just one of many mediating factors. Another possible explanation is that LVH perhaps mediates the effect of intensive BP lowering on certain CVD outcomes but not others. It is notable that intensive BP lowering was associated with a lower risk of heart failure but not myocardial infarction or acute coronary syndromes in SPRINT; all are SPRINT secondary outcomes. 34 Compared with a composite of CVD events 33 or coronary heart disease, 34 LVH is an established predictor heart failure and is a component of the Framingham heart failure risk prediction score. 35 This may explain why intensive BP lowering selectively reduced the risk of heart failure more than other SPRINT secondary CVD outcomes. Because of the relatively small number of individual SPRINT secondary CVD outcomes (heart failure, stoke, myocardial infarction, and death resulting from any cause), we could not usefully examine the associations among intensive BP lowering, individual CVD outcomes, and LVH; that is, there is a statistical power limitation.
On the basis of our results in SPRINT, which included patients with hypertension but no diabetes mellitus, and taking into account our prior results from the AC-CORD BP trial, which included patients with hypertension and diabetes mellitus, 3 it could be suggested that intensive treatment to a target SBP of <120 mm Hg in hypertensive patients at high risk of CVD will reduce the risk of LVH. Nevertheless, there could be variations in the response to the effect of intensive BP lowering on LVH among certain groups. In our subgroup analysis, those with prior CVD showed more benefit for regression of LVH, although they did not show more benefit for developing new incident LVH during the follow-up period.
Limitations and Strengths
Our results should be read in the context of certain limitations and methodological considerations. By design, the SPRINT trial had an open-label design, which could lead to bias in the identification of certain types of end points. However, it is unlikely that the openlabel design had an impact on the ascertainment of LVH, which was measured from ECGs that were read centrally at an ECG core laboratory by investigators blinded to treatment assignment. Because SPRINT was a treatment strategy trial in the sense that it examined the effect of different levels of SBP rather than the effect of individual drugs, we could not separate the impact of lowering BP from the impact of individual medications. Another limitation is that it may not be appropriate to generalize our findings to other types of hypertension patients not included in SPRINT such as those with lower CVD risk, with prior stroke, <50 years of age, or with diabetes mellitus. Nevertheless, some of these groups such as those with hypertension and diabetes mellitus 3 have been examined before, which actually makes our study unique.
We defined LVH using ECG, not imaging (echocardiography or cardiac magnetic resonance imaging). Although imaging provides a more accurate assessment of LVH than ECG, any misclassification should have affected both arms equally, and hence, the effect should be balanced. Nevertheless, significant nondifferential misclassification of LVH could affect our ability to estimate the true mediation of LVH, which could explain the marginal attenuation of the CVD risk associated with intensive BP after adjustment for LVH as a time-varying covariate. More important, LVH detected by ECG has been shown to be predictive of poor outcomes in a similar way as LVH detected by imaging. [36] [37] [38] [39] These findings, along with its wide availability and low cost, have made ECG the ideal tool for the initial evaluation of patients with hypertension to detect LVH. 40 In a related point, we decided to use Cornell voltage to define LVH because of its simple calculation that incorporates sex-specific cutoff points. As one of the most commonly used LVH criteria, it has had good diagnostic performance in multiethnic settings compared with other LVH criteria and high prognostic significance as a predictor for CVD events, 41 and it is not affected by obesity. 42 Because there are several other LVH criteria, it could be argued that our results should be applied only to Cornell voltage LVH. However, we performed sensitivity analyses using 3 other commonly used LVH criteria (Cornell voltage product, Sokolow-Lyon, and Minnesota Code ECG classification) and observed similar results. Furthermore, the current recommendations for the use of ECG criteria for detecting cardiac chamber enlargement 18 do not favor or recommend one set of LVH criteria over the other (ie, any LVH criteria could be used as long as specifically named). Therefore, using Cornell voltage or another criterion should serve the purpose and be in accordance with these recommendations.
Despite these limitations, this analysis is the first report from a well-designed large clinical trial in which the effect of intensive BP lowering on LVH in patients with hypertension without diabetes mellitus is examined. The strengths of our study include large sample size, racially diverse population with representation of both sexes, inclusion of a large proportion of patients >75 years old, random assignment of participants to treatment arms resulting in balanced groups at baseline, standardized data collection including ECG data that were centrally read, and achievement and maintenance of the intended differences in SBP between arms throughout the study.
Conclusions
In patients with hypertension but no diabetes mellitus, intensive BP lowering (target <120 mm Hg) reduces the risk of LVH by preventing the development of new LVH in those without LVH and causing the regression of LVH in those with existing LVH. This favorable impact on LVH, however, does not explain most of the reduction in CVD events associated with intensive BP lowering in SPRINT. These findings add further evidence of the benefits of the intensive BP lowering in patients with hypertension and suggest that these benefits go beyond reducing the hemodynamic stress on the cardiac structure. Understanding the mediating factors and the mechanisms by which intensive BP lowering affects the cardiovascular system would help in better selection of those who may benefit with least harm.
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